Auf dem diesjährigen Kongress bringt das wissenschaftliche Programm von Roche weltweite Expertinnen und Experten zusammen, um klinische Erkenntnisse und Real-World-Evidence zu den drängendsten klinischen Fragen der heutigen Neuroimmunologie auszutauschen.
Den MSToronto (ACTRIMS-ECTRIMS) von zuhause aus erleben:
- Podcast Nervennahrung: Täglich mit klinisch relevanten Beiträge aus allen Bereichen der Neurologie
- Jetzt anmelden Post-Kongress-Webinar: “Hot Topics @ ECTRIMS 2026” ´. Zusammengefasst von renommierten Expert:innen - Live via Zoom.
- Wir fassen nach dem Kongress die Highlights und spannendsten Daten für Sie zusammen
Ihre Teilnahme vor Ort:
- Satellite Symposien: Nehmen Sie an unseren MS und NMOSD Satelliten Symposien mit hochkarätiger Besetzung teil
- Industry Showcases: Wir haben dieses Jahr drei spannende Showcases für Sie, unter Anderem: "Time for What Matters: Ocrevus SC"
- Roche und Expert:innen Live beim MSToronto: Booth 300
Satellite Symposium
1:15 - 2:15 PM
Lecture Hall G
Acting early: high-efficacy intervention across the MS continuum
This symposium will explore evolving approaches to early MS management, focusing on the importance of timely intervention of high-efficacy therapies in young people with MS or those with mild disease, and the gap between evidence and real-world practice. Faculty will consider how current understanding of MS and emerging data should inform treatment decisions early in the disease course, regardless of disease activity or patient profile.
Drawing on clinical and real-world evidence, the session will address key considerations including preservation of independence and quality of life, family planning and outcomes associated with early versus delayed intervention across diverse patient populations. An interactive, question-led format will support discussion of real-world clinical decision-making and evolving practice.
Wednesday, October 21
Lecture Hall G
1:15 - 2:15 PM
This Roche-sponsored event is intended for HCPs and members of the scientific community and is not intended for physicians practising in the United States (US).
Roche proactively tries to ensure medical education is as widely accessible as possible for HCPs all over the world.
This event is organised and funded by Roche. The content of this event is owned by: F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland.
© 2026 F. Hoffmann-La Roche Ltd. All trademarks mentioned herein are protected by law. www.roche.com.
Satellite Symposium
1:15 - 2:15 PM
Lecture Hall G
MS Disease Biology in Focus: Targeting Peripheral and CNS Mechanisms
Symposium Learning Objectives:
- Understand the roles of concurrent relapsing and progressive biology in MS across both the periphery and CNS
- Recognize the unmet need for more comprehensive targeting of both peripheral and CNS pathways, and the potential of BTK inhibition to address this gap
- Appraise the clinical data for BTK inhibitors in MS, and evaluate their impact on relapsing and progressive biology
- Become confident in interpreting data across trials in the context of study methodology and patient populations
- Understand the value of emerging markers of progression in uncovering the impact of BTK inhibitors
Thursday, October 22
Lecture Hall G
1:15 - 2:15 PM
BTK, Bruton’s Tyrosine Kinase; CNS, Central Nervous System; HCPs, healthcare professionals; MS, Multiple Sclerosis
This Roche-sponsored event is intended for HCPs and members of the scientific community and is not intended for physicians practising in the United States (US).
Roche proactively tries to ensure medical education is as widely accessible as possible for HCPs all over the world.
This event is organised and funded by Roche. The content of this event is owned by: F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland.
© 2026 F. Hoffmann-La Roche Ltd. All trademarks mentioned herein are protected by law. www.roche.com.
Satellite Symposium (Chugai-supported)
5:30 - 6:30 PM
Lecture Hall 714
News You Can Use: Progress in Clinical Neuroimmunology
This satellite symposium explores the evolving landscape of neuroimmunological conditions, specifically focusing on NMOSD and MOGAD. The program emphasizes the critical importance of early intervention and lifelong therapy to manage the relentless nature of these diseases and prevent disastrous outcomes.
Key topics include pathophysiological mechanisms—such as the role of IL-6—and their influence on clinical decision-making and long-term prognosis. Additionally, the session addresses clinical distinctions between NMOSD and MOGAD, highlighting demographic challenges and the dynamic role of imaging in integrating new research findings.
Wednesday, October 21
Lecture Hall 714
5:30 - 6:30 PM
HCPs, healthcare professionals; IL-6, Interleukin-6; MOGAD, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease; NMOSD, Neuromyelitis Optica Spectrum Disorder
This Roche-sponsored event is intended for HCPs and members of the scientific community and is not intended for physicians practising in the United States (US).
Roche proactively tries to ensure medical education is as widely accessible as possible for HCPs all over the world.
This event is organised and funded by Roche. The content of this event is owned by: F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland.
© 2026 F. Hoffmann-La Roche Ltd. All trademarks mentioned herein are protected by law. www.roche.com.
CME Symposium (Genentech-supported)
1:15 - 2:15 PM
Lecture Hall 801
Treating All of MS: Unifying Strategies to Target Relapse and Progression in a Shifting Clinical Landscape
This program is planned, organized and hosted independently by Efficient CME and CME Outfitters. The program examines the evolving understanding of MS as a spectrum, utilizing the topographical model to highlight overlapping pathologies between relapsing and progressive phenotypes. It addresses the importance of early and persistent PIRA and the influence of the 2024 McDonald Criteria on a unified diagnosis.
Discussions include the role of B-cell therapies and the optimal combination of biomarkers like NfL and GFAP to monitor disease. Additionally, the symposium integrates the positioning of BTK inhibitors, such as fenebrutinib and tolebrutinib, within the treatment algorithm for both relapsing and progressive disease states.
Thursday, October 22
Lecture Hall 801
1:15 - 2:15 PM
BTK, Bruton’s Tyrosine Kinase; CME, Continuing Medical Education; CNS, Central Nervous System; GFAP, Glial Fibrillary Acidic Protein; HCPs, healthcare professionals; MS, Multiple Sclerosis; NfL, Neurofilament Light Chain; PIRA, Progression Independent of Relapse Activity
Please remember that this Genentech-supported program is an independent CME activity conducted by an independent medical education company and intended for HCPs and members of the scientific community. The content of this activity is owned by the independent medical education company. If you choose to participate, be aware that Genentech/Roche personnel must be silent observers and must not engage in the activity in any way, including discussions, Q&A, and chat functions.
CME Symposium (Genentech-supported)
1:15 - 2:15 PM
Lecture Hall 801
Unifying Evolving Paradigms in MS: From Early Diagnosis to Next‑gen Treatment and Monitoring
This program is planned, organized and hosted independently by Vindico Medical Education.This symposium focuses on unifying MS paradigms through the application of the 2024 McDonald criteria, including optic nerve integration and advanced MRI biomarkers like CVS and PRLs. Participants will explore how to recognize subtle, early, and prodromal presentations using OCT and VEP findings.
The program provides an overview of high-efficacy therapies and the potential impact of BTK inhibitors—such as fenebrutinib, tolebrutinib, and remibrutinib—on inflammatory and neurodegenerative activity. Finally, the session reviews the integration of serum biomarkers like sNfL and sGFAP with digital monitoring tools to detect subclinical disease activity and progression risk.
Wednesday, October 21
Lecture Hall 801
1:15 - 2:15 PM
BTK, Bruton’s Tyrosine Kinase; CME, Continuing Medical Education; CVS, Central Vein Sign; HCPs, healthcare professionals; MS, Multiple Sclerosis; MRI, Magnetic Resonance Imaging; OCT, Optical Coherence Tomography; PRLs, Paramagnetic Rim Lesions; sGFAP, Serum Glial Fibrillary Acidic Protein; sNfL, Serum Neurofilament Light Chain; VEP, Visual Evoked Potentials
Please remember that this Genentech-supported program is an independent CME activity conducted by an independent medical education company and intended for HCPs and members of the scientific community. The content of this activity is owned by the independent medical education company. If you choose to participate, be aware that Genentech/Roche personnel must be silent observers and must not engage in the activity in any way, including discussions, Q&A, and chat functions.
In conversation with
Dr Barry A Singer
The MS Center for Innovations in Care
Missouri Baptist Medical Center
St Louis, Missouri
USA
For a decade, Ocrevus has defined high-efficacy care in Multiple Sclerosis. Now, Ocrevus SC is redefining the patient experience. By merging the best MS treatment power of B-cell depletion with a twice-yearly 10-minute subcutaneous delivery, we are giving patients back their most valuable resource: time.
GOALS FOR THE INDUSTRY SHOWCASE:
- Differentiate OCR SC from other aCD20
- Present OCR SC value proposition by covering the unmet needs and gaps in the market
- Share real cases of how OCR SC delivers in efficacy with superior convenience while maintaining the same safety profile
This Roche-sponsored event is intended for healthcare professionals. The data and presentations are based on European Medicines Agency (EMA) regulations and labels, and are not intended for physicians practicing in the United States of America. Content presented herein may discuss formulations, indications, or data that are not approved or aligned with the labelling in other jurisdictions. Local prescribing information should always be consulted.
Subcutaneous Ocrevus is not authorized for sale in Canada.
Roche proactively tries to ensure medical education is as widely accessible as possible for HCPs all over the world.
This event is organised and funded by Roche. The content of this event is owned by: F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland.
© 2026 F. Hoffmann-La Roche Ltd. All trademarks mentioned herein are protected by law. www.roche.com.
Industry Showcase
1:00 - 1:20 PM
Industry Theatre
Shaping MS care: Scientific innovation to improve patient outcomes
This showcase dives into the current scientific understanding of multiple sclerosis, exploring the mechanisms driving disease progression and the latest advancements in diagnostics and therapies. Experts will discuss groundbreaking research approaches and innovations, highlighting how these discoveries could be translated into medical practice to optimize patient outcomes. Join us as we chart the path forward for MS management.
Wednesday, October 21
Industry Theatre
1:00 - 1:20 PM
This Roche-sponsored event is intended for HCPs and members of the scientific community and is not intended for physicians practising in the United States (US).
Roche proactively tries to ensure medical education is as widely accessible as possible for HCPs all over the world.
This event is organised and funded by Roche. The content of this event is owned by: F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland.
© 2026 F. Hoffmann-La Roche Ltd. All trademarks mentioned herein are protected by law. www.roche.com.
Industry Showcase
1:35 - 1:55 PM
Industry Theatre
Hit the target - IL-6 in rare neuroimmunological conditions
The IL-6 signaling pathway is well recognised as a central driver in rare CNS autoimmune conditions and has opened a new therapeutic chapter. This meeting will explore the multifaceted role of IL-6—a pleiotropic cytokine that not only fuels inflammation but also compromises the blood-brain barrier and promotes the survival of pathogenic plasmablasts through upstream mechanisms. As we look toward the future of rare disease management, we will evaluate the clinical value of IL-6 inhibition across a spectrum of disorders, including NMOSD, MOGAD, and Autoimmune Encephalitis.
The clinical expert will discuss how targeting this specific "cytokine hub" can reduce relapse risk, manage long term disability with an acceptable long term safety and tolerability profile and convenient administration.
Thursday, October 22
Industry Theatre
1:35 - 1:55 PM
CNS, Central Nervous System; IL-6, Interleukin-6; MOGAD, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease; NMOSD, Neuromyelitis Optica Spectrum Disorder
This Roche-sponsored event is intended for HCPs and members of the scientific community and is not intended for physicians practising in the United States (US).
Roche proactively tries to ensure medical education is as widely accessible as possible for HCPs all over the world.
This event is organised and funded by Roche. The content of this event is owned by: F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland.
© 2026 F. Hoffmann-La Roche Ltd. All trademarks mentioned herein are protected by law. www.roche.com.
